Robert Ross

Robert Ross is a medical oncologist turned biotech executive and the founding CEO of Clasp Therapeutics, a Baltimore-based clinical-stage immuno-oncology company building bispecific T cell engagers that target mutated cancer driver peptides presented by HLA with what the company calls absolute specificity. Launched in March 2024 with a $150 million Series A from Third Rock Ventures, Novo Holdings and Catalio Capital, Clasp is commercializing science from Johns Hopkins legends Bert Vogelstein and Drew Pardoll. Ross previously ran Surface Oncology through its acquisition by Coherus, led oncology at bluebird bio, and trained as a physician at Columbia, Harvard, Stanford and UCSF.